Bectumomab (IMMU-LL 2) is a humanized IgG2a monoclonal antibody specifically targeting human CD22, an antigen predominantly expressed on the surface of B cells. This antibody is engineered as an anti-lymphoma agent, primarily utilized in the detection and management of non-Hodgkin's lymphoma (NHL). Bectumomab is compatible for use in imaging studies when conjugated with technetium-99 (Tc99m LL2 Fab), facilitating the assessment of lymphoma staging in both recurrent and newly diagnosed cases. Additionally, it serves as a valuable tool in evaluating the efficacy of targeting prior to the initiation of radioimmunotherapy (RIT). This antibody's specificity and application in advanced diagnostic imaging and therapy make it a critical component in lymphoma research and clinical practice.
Bectumomab (IMMU-LL 2) is a humanized IgG2a monoclonal antibody specifically targeting human CD22, an antigen predominantly expressed on the surface of B cells. This antibody is engineered as an anti-lymphoma agent, primarily utilized in the detection and management of non-Hodgkin's lymphoma (NHL). Bectumomab is compatible for use in imaging studies when conjugated with technetium-99 (Tc99m LL2 Fab), facilitating the assessment of lymphoma staging in both recurrent and newly diagnosed cases. Additionally, it serves as a valuable tool in evaluating the efficacy of targeting prior to the initiation of radioimmunotherapy (RIT). This antibody's specificity and application in advanced diagnostic imaging and therapy make it a critical component in lymphoma research and clinical practice.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
